Based on the Treace Medical Concepts Inc stock forecast from 6 analysts, the average analyst target price for Treace Medical Concepts Inc is USD 11.20 over the next 12 months. Treace Medical Concepts Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Treace Medical Concepts Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Treace Medical Concepts Inc’s stock price was USD 7.61. Treace Medical Concepts Inc’s stock price has changed by -9.30% over the past week, -11.20% over the past month and -37.83% over the last year.
No recent analyst target price found for Treace Medical Concepts Inc
No recent average analyst rating found for Treace Medical Concepts Inc
Company Overview Treace Medical Concepts Inc
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. Read Less
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three plan...Read More
Frequently Asked Questions About Treace Medical Concepts Inc (TMCI) Stock
Based on ratings from 6 analysts Treace Medical Concepts Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and 7 hold ratings.
Unfortunately we do not have enough data on TMCI's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for TMCI is USD 11.20 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on TMCI's stock to indicate if its overvalued.
The last closing price of TMCI's stock was USD 7.61.
The most recent market capitalization for TMCI is USD 0.52B.
Based on targets from 6 analysts, the average taret price for TMCI is projected at USD 11.20 over the next 12 months.
This means that TMCI's stock price may go up by +57.75% over the next 12 months.
We can't find any ETFs which contains Treace Medical Concepts Inc's stock.
As per our most recent records Treace Medical Concepts Inc has 477 Employees.
Treace Medical Concepts Inc's registered address is 100 Palmetto Park Place, Ponte Vedra, FL, United States, 32081.
You can get more information about it from Treace Medical Concepts Inc's website at https://www.treace.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Treace Medical Concepts Inc (TMCI) Stock
Based on ratings from 6 analysts Treace Medical Concepts Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and 7 hold ratings.
Unfortunately we do not have enough data on TMCI's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for TMCI is USD 11.20 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on TMCI's stock to indicate if its overvalued.
The last closing price of TMCI's stock was USD 7.61.
The most recent market capitalization for TMCI is USD 0.52B.
Based on targets from 6 analysts, the average taret price for TMCI is projected at USD 11.20 over the next 12 months.
This means that TMCI's stock price may go up by +57.75% over the next 12 months.
We can't find any ETFs which contains Treace Medical Concepts Inc's stock.
As per our most recent records Treace Medical Concepts Inc has 477 Employees.
Treace Medical Concepts Inc's registered address is 100 Palmetto Park Place, Ponte Vedra, FL, United States, 32081.
You can get more information about it from Treace Medical Concepts Inc's website at https://www.treace.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TMCI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
